Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
CONCLUSION: We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.PMID:37812963 | DOI:10.1016/j.breast.2023.103586 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: Jan Paredes Mogica Haiming Tang Yuanxin Liang Minghao Zhong Pei Hui Malini Harigopal Uma Krishnamurti Neal A Fischbach Haiying Zhan Source Type: research
Consumer experiences of shame in clinical encounters for breast cancer treatment. "Who do you think you are- Angelina Jolie?"
CONCLUSIONS: Shame can be experienced in a range of situations, from scrutiny of the naked body to comments from health professionals. The impact of these experiences is profound, and the feelings of shame are carried for many years. These findings can inform strategies to support consumers and educate health professionals with the aim of reducing harm related to cancer treatment.PMID:37812962 | DOI:10.1016/j.breast.2023.103587 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: M E Brennan K Bell G Hamid J Gilchrist J Gillingham Source Type: research
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
CONCLUSION: We conclude that reduced HER2 expression by IHC following neoadjuvant treatment was associated with lower recurrence rates in HER2 IHC 3+ breast cancer. If confirmed, RD HER2 IHC expression could be used as a prognostic biomarker to stratify patients in adjuvant trials and identify patients who may benefit from more intensive adjuvant therapy and post therapy surveillance.PMID:37812963 | DOI:10.1016/j.breast.2023.103586 (Source: Breast)
Source: Breast - October 9, 2023 Category: Cancer & Oncology Authors: Jan Paredes Mogica Haiming Tang Yuanxin Liang Minghao Zhong Pei Hui Malini Harigopal Uma Krishnamurti Neal A Fischbach Haiying Zhan Source Type: research
An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
CONCLUSION: The use of pegfilgrastim as secondary prophylaxis was effective and safe for preventing FN in patients with breast cancer who were treated with chemotherapy.PMID:37802015 | DOI:10.1016/j.breast.2023.103585 (Source: Breast)
Source: Breast - October 6, 2023 Category: Cancer & Oncology Authors: Anbok Lee Taewoo Kang Su Hwan Kang Woo-Chan Park Woosung Lim Myung-Chul Chang Hyun Yul Kim Jeong-Yoon Song Jihyoun Lee Kyung Do Byun Hyun-Ah Kim Gil Soo Son Ju-Yeon Kim Se Jeong Oh Min Sung Chung Young Jin Choi Hyuk-Jai Shin Jong Min Baek Youngbum Yoo Eun Source Type: research
An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
CONCLUSION: The use of pegfilgrastim as secondary prophylaxis was effective and safe for preventing FN in patients with breast cancer who were treated with chemotherapy.PMID:37802015 | DOI:10.1016/j.breast.2023.103585 (Source: Breast)
Source: Breast - October 6, 2023 Category: Cancer & Oncology Authors: Anbok Lee Taewoo Kang Su Hwan Kang Woo-Chan Park Woosung Lim Myung-Chul Chang Hyun Yul Kim Jeong-Yoon Song Jihyoun Lee Kyung Do Byun Hyun-Ah Kim Gil Soo Son Ju-Yeon Kim Se Jeong Oh Min Sung Chung Young Jin Choi Hyuk-Jai Shin Jong Min Baek Youngbum Yoo Eun Source Type: research
An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer
CONCLUSION: The use of pegfilgrastim as secondary prophylaxis was effective and safe for preventing FN in patients with breast cancer who were treated with chemotherapy.PMID:37802015 | DOI:10.1016/j.breast.2023.103585 (Source: Breast)
Source: Breast - October 6, 2023 Category: Cancer & Oncology Authors: Anbok Lee Taewoo Kang Su Hwan Kang Woo-Chan Park Woosung Lim Myung-Chul Chang Hyun Yul Kim Jeong-Yoon Song Jihyoun Lee Kyung Do Byun Hyun-Ah Kim Gil Soo Son Ju-Yeon Kim Se Jeong Oh Min Sung Chung Young Jin Choi Hyuk-Jai Shin Jong Min Baek Youngbum Yoo Eun Source Type: research
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
CONCLUSION: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.PMID:37783133 | PMC:PMC10551556 | DOI:10.1016/j.breast.2023.103583 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Source Type: research
The King is in the altogether: Radiation therapy after oncoplastic breast surgery
Breast. 2023 Sep 25;72:103584. doi: 10.1016/j.breast.2023.103584. Online ahead of print.ABSTRACTBreast cancer is the most common malignancy, and the majority of the patients are diagnosed at an early disease stage. Breast conservation is the preferred locoregional approach, and oncoplastic breast conservation surgery is becoming more popular. This narrative review aims to discuss the challenges and uncertainties in target volume definition for postoperative radiation after these procedures, to improve radiation therapy decisions and encourage multidisciplinary.PMID:37783134 | DOI:10.1016/j.breast.2023.103584 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Orit Kaidar-Person Birgitte Vrou Offersen Trine Tramm Peer Christiansen Tine Engberg Damsgaard Ashutosh Kothari Philip Poortmans Source Type: research
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
CONCLUSION: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.PMID:37783133 | DOI:10.1016/j.breast.2023.103583 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Source Type: research
The King is in the altogether: Radiation therapy after oncoplastic breast surgery
Breast. 2023 Sep 25;72:103584. doi: 10.1016/j.breast.2023.103584. Online ahead of print.ABSTRACTBreast cancer is the most common malignancy, and the majority of the patients are diagnosed at an early disease stage. Breast conservation is the preferred locoregional approach, and oncoplastic breast conservation surgery is becoming more popular. This narrative review aims to discuss the challenges and uncertainties in target volume definition for postoperative radiation after these procedures, to improve radiation therapy decisions and encourage multidisciplinary.PMID:37783134 | DOI:10.1016/j.breast.2023.103584 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Orit Kaidar-Person Birgitte Vrou Offersen Trine Tramm Peer Christiansen Tine Engberg Damsgaard Ashutosh Kothari Philip Poortmans Source Type: research
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
CONCLUSION: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.PMID:37783133 | DOI:10.1016/j.breast.2023.103583 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Source Type: research
The King is in the altogether: Radiation therapy after oncoplastic breast surgery
Breast. 2023 Sep 25;72:103584. doi: 10.1016/j.breast.2023.103584. Online ahead of print.ABSTRACTBreast cancer is the most common malignancy, and the majority of the patients are diagnosed at an early disease stage. Breast conservation is the preferred locoregional approach, and oncoplastic breast conservation surgery is becoming more popular. This narrative review aims to discuss the challenges and uncertainties in target volume definition for postoperative radiation after these procedures, to improve radiation therapy decisions and encourage multidisciplinary.PMID:37783134 | DOI:10.1016/j.breast.2023.103584 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Orit Kaidar-Person Birgitte Vrou Offersen Trine Tramm Peer Christiansen Tine Engberg Damsgaard Ashutosh Kothari Philip Poortmans Source Type: research
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
CONCLUSION: Median first-line PFS improved since 2014, mainly due to the introduction of pertuzumab. The outcome of patients with liver metastases appears to have improved in recent years. Patients with brain metastases had the worst PFS, which also did not improve over time.PMID:37783133 | DOI:10.1016/j.breast.2023.103583 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Massimo Di Maio Claudia Bighin Francesco Schettini Tommaso Ruelle Laura Marandino Alessandra Fabi Carmine De Angelis Mario Giuliano Pietro De Placido Michelino De Laurentiis Ferdinando Riccardi Caterina Picotto Fabio Puglisi Lucia Del Mastro Grazia Arpino Source Type: research
The King is in the altogether: Radiation therapy after oncoplastic breast surgery
Breast. 2023 Sep 25;72:103584. doi: 10.1016/j.breast.2023.103584. Online ahead of print.ABSTRACTBreast cancer is the most common malignancy, and the majority of the patients are diagnosed at an early disease stage. Breast conservation is the preferred locoregional approach, and oncoplastic breast conservation surgery is becoming more popular. This narrative review aims to discuss the challenges and uncertainties in target volume definition for postoperative radiation after these procedures, to improve radiation therapy decisions and encourage multidisciplinary.PMID:37783134 | DOI:10.1016/j.breast.2023.103584 (Source: Breast)
Source: Breast - October 2, 2023 Category: Cancer & Oncology Authors: Orit Kaidar-Person Birgitte Vrou Offersen Trine Tramm Peer Christiansen Tine Engberg Damsgaard Ashutosh Kothari Philip Poortmans Source Type: research
Expert UK consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: A modified Delphi panel
CONCLUSIONS: The results may be a valuable reference point to guide recurrence risk assessment and decision-making after surgery in the HER2-negative eBC population.PMID:37769521 | PMC:PMC10539921 | DOI:10.1016/j.breast.2023.103582 (Source: Breast)
Source: Breast - September 28, 2023 Category: Cancer & Oncology Authors: E R Copson J E Abraham J P Braybrooke D Cameron S A McIntosh C O Michie A F C Okines C Palmieri F Raja R Roylance S Spensley Delphi panellists Source Type: research
